Table 1.
Photodynamic therapy studies for early-stage non-small cell lung cancer in the last 10 years
| Publication | Indication | Photosensitizer | No. of Patients | Outcome |
|---|---|---|---|---|
| Furukawa et al., 2005 (49) | CLELC | Porfimer sodium | 93 | CR: 92.8%/58.1% (less/greater than 1-cm lesion) |
| Corti et al., 2007 (51) | CLELC | Porfimer sodium II (50%), hematoporphyrin derivative (50%) | 40 | CR: 72%, PR: 20%, NR: 6% |
| Usuda et al., 2007 (52) | CLELC | Talaporfin sodium | 29 | CR: 92.1%, PR: 7.9% |
| Moghissi et al., 2007 (50) | CLELC | Porfimer sodium | 21 | CR: 100% |
| Endo et al., 2009 (41) | CLELC | Porfimer sodium | 48 | CR: 94% |
| Usuda et al., 2010 (54) | CLELC | Talaporfin sodium | 75 | CR: 94%/90.4% (less/greater than 1-cm lesion) |
| Usuda et al., 2010 (53) | CLELC | Talaporfin sodium | 64 | CR: 100% |
Definition of abbreviations: CLELC = centrally located early lung cancer; CR = complete response; NR = no response; PR = partial response.